India, March 17 -- image credit- shutterstock

Peptris Technologies, a Bengaluru-based AI-powered drug discovery startup, has entered into a licensing agreement with US-based Revio Therapeutics, a specialty pharma startup focused on repurposing and optimizing approved medicines.

Under the agreement, Peptris is licensing its preclinical-stage asset, PEPR124 (RT001) for an undisclosed amount to Revio Therapeutics for further development in Duchenne Muscular Dystrophy (DMD). The agreement is expected to accelerate Peptris' AI-powered drug discovery efforts and expand its footprint in global biotech markets.

DMD is a rare genetic disorder primarily affecting boys, leading toprogressive muscle degeneration, severe disability, and reduced lif...